Drug Profile
Tasisulam - Eli Lilly
Alternative Names: LY 57636; LY573636; LY573636-sodium; Tasisulam sodiumLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules; Sulfonamides
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 27 Apr 2012 Discontinued - Phase-I for Solid tumours in France (IV)
- 18 Apr 2012 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)
- 18 Apr 2012 Discontinued - Phase-I for Renal cancer in Canada (IV)